Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Conmed (CNMD) over the last 16 years, with Q4 2025 value amounting to $4.1 million.

  • Conmed's Depreciation and Depletion fell 316.74% to $4.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $17.1 million, marking a year-over-year increase of 324.0%. This contributed to the annual value of $17.1 million for FY2025, which is 324.0% up from last year.
  • Conmed's Depreciation and Depletion amounted to $4.1 million in Q4 2025, which was down 316.74% from $4.4 million recorded in Q3 2025.
  • Over the past 5 years, Conmed's Depreciation and Depletion peaked at $4.8 million during Q1 2021, and registered a low of $3.8 million during Q3 2021.
  • Over the past 5 years, Conmed's median Depreciation and Depletion value was $4.1 million (recorded in 2022), while the average stood at $4.1 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first tumbled by 1524.07% in 2022, then skyrocketed by 722.69% in 2025.
  • Quarter analysis of 5 years shows Conmed's Depreciation and Depletion stood at $4.0 million in 2021, then grew by 1.31% to $4.0 million in 2022, then grew by 0.62% to $4.1 million in 2023, then increased by 3.63% to $4.2 million in 2024, then decreased by 3.17% to $4.1 million in 2025.
  • Its Depreciation and Depletion stands at $4.1 million for Q4 2025, versus $4.4 million for Q3 2025 and $4.5 million for Q2 2025.